JP2022543742A5 - - Google Patents

Info

Publication number
JP2022543742A5
JP2022543742A5 JP2022503794A JP2022503794A JP2022543742A5 JP 2022543742 A5 JP2022543742 A5 JP 2022543742A5 JP 2022503794 A JP2022503794 A JP 2022503794A JP 2022503794 A JP2022503794 A JP 2022503794A JP 2022543742 A5 JP2022543742 A5 JP 2022543742A5
Authority
JP
Japan
Prior art keywords
cells
item
antigen
promoter
fusion polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022503794A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022543742A (ja
JP7676358B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/042753 external-priority patent/WO2021016174A1/en
Publication of JP2022543742A publication Critical patent/JP2022543742A/ja
Publication of JP2022543742A5 publication Critical patent/JP2022543742A5/ja
Priority to JP2024198293A priority Critical patent/JP2025015619A/ja
Application granted granted Critical
Publication of JP7676358B2 publication Critical patent/JP7676358B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022503794A 2019-07-19 2020-07-20 免疫療法のための融合ポリペプチド Active JP7676358B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024198293A JP2025015619A (ja) 2019-07-19 2024-11-13 免疫療法のための融合ポリペプチド

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962876338P 2019-07-19 2019-07-19
US62/876,338 2019-07-19
PCT/US2020/042753 WO2021016174A1 (en) 2019-07-19 2020-07-20 Fusion polypeptide for immunotherapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024198293A Division JP2025015619A (ja) 2019-07-19 2024-11-13 免疫療法のための融合ポリペプチド

Publications (3)

Publication Number Publication Date
JP2022543742A JP2022543742A (ja) 2022-10-14
JP2022543742A5 true JP2022543742A5 (cg-RX-API-DMAC7.html) 2023-07-28
JP7676358B2 JP7676358B2 (ja) 2025-05-14

Family

ID=74192452

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022503794A Active JP7676358B2 (ja) 2019-07-19 2020-07-20 免疫療法のための融合ポリペプチド
JP2024198293A Pending JP2025015619A (ja) 2019-07-19 2024-11-13 免疫療法のための融合ポリペプチド

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024198293A Pending JP2025015619A (ja) 2019-07-19 2024-11-13 免疫療法のための融合ポリペプチド

Country Status (11)

Country Link
US (1) US20220133802A1 (cg-RX-API-DMAC7.html)
EP (1) EP3999079A4 (cg-RX-API-DMAC7.html)
JP (2) JP7676358B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220035471A (cg-RX-API-DMAC7.html)
CN (1) CN115298208A (cg-RX-API-DMAC7.html)
AU (1) AU2020315796A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022000976A2 (cg-RX-API-DMAC7.html)
CA (1) CA3148072A1 (cg-RX-API-DMAC7.html)
IL (1) IL289887A (cg-RX-API-DMAC7.html)
MX (1) MX2022000769A (cg-RX-API-DMAC7.html)
WO (1) WO2021016174A1 (cg-RX-API-DMAC7.html)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240076351A1 (en) * 2021-01-15 2024-03-07 Seattle Children's Hospital D/B/A Seattle Children's Research Institute Hybrid and truncated immune cell proteins
EP4305174A4 (en) * 2021-03-10 2025-04-30 B.G. Negev Technologies and Applications Ltd., at Ben-Gurion University REPORTER CELLS EXPRESSING CHIMERIC POLYPEPTIDES TO DETERMINE THE PRESENCE AND/OR ACTIVITY OF IMMUNE CHECKPOINT MOLECULES
US12486310B2 (en) 2021-04-21 2025-12-02 Brigham Young University Metastasis inhibiting protein
WO2022233956A1 (en) 2021-05-05 2022-11-10 Immatics Biotechnologies Gmbh Antigen binding proteins specifically binding prame
WO2023020471A1 (en) * 2021-08-16 2023-02-23 Utc Therapeutics (Shanghai) Co., Ltd. Cd123-targetting antibodies and uses thereof in cancer therapies
WO2023081542A1 (en) * 2021-11-02 2023-05-11 Christopher Mendoza Metastasis inhibiting protein
JP2025501272A (ja) 2021-12-28 2025-01-17 ムネモ・セラピューティクス 不活性化されたsuv39h1及び改変tcrを有する免疫細胞
AU2023209589A1 (en) 2022-01-21 2024-08-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Modulation of suv39h1 expression by rnas
EP4279085A1 (en) 2022-05-20 2023-11-22 Mnemo Therapeutics Compositions and methods for treating a refractory or relapsed cancer or a chronic infectious disease
WO2024062138A1 (en) 2022-09-23 2024-03-28 Mnemo Therapeutics Immune cells comprising a modified suv39h1 gene
WO2024086842A2 (en) * 2022-10-21 2024-04-25 Memorial Sloan-Kettering Cancer Center Cells and compositions for treating cancer
JP2025536892A (ja) * 2022-10-21 2025-11-12 メモリアル スローン ケタリング キャンサー センター 抗cd70キメラ受容体を発現する細胞及びその用途
TW202442689A (zh) 2023-03-03 2024-11-01 美商亞森諾生物科學公司 靶向psma及ca9之系統
EP4680748A1 (en) 2023-03-13 2026-01-21 Arsenal Biosciences, Inc. Synthetic pathway activators
WO2024227145A1 (en) * 2023-04-27 2024-10-31 Memorial Sloan-Kettering Cancer Center Enhanced fusion polypeptide for immunotherapy
WO2026078056A1 (en) * 2024-10-09 2026-04-16 Leibniz-Institut Für Immuntherapie (Lit) Engineered tnfr ligands

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1975A (en) 1841-02-12 Manner of constructing corn-shellers
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
JPS6412935A (en) 1987-07-02 1989-01-17 Mitsubishi Electric Corp Constant-speed travel device for vehicle
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US6436703B1 (en) 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
AU2002221780A1 (en) * 2000-10-31 2002-05-15 F.Hoffmann-La Roche Ag Nucleic acids encoding cd40/cd40l chimeric polypeptides, methods for their production and uses thereof
US7446190B2 (en) 2002-05-28 2008-11-04 Sloan-Kettering Institute For Cancer Research Nucleic acids encoding chimeric T cell receptors
GB0620934D0 (en) 2006-10-20 2006-11-29 Cambridge Antibody Tech Protein variants
US8389282B2 (en) 2007-03-30 2013-03-05 Memorial Sloan-Kettering Cancer Center Constitutive expression of costimulatory ligands on adoptively transferred T lymphocytes
WO2010098788A2 (en) 2008-08-25 2010-09-02 Amplimmune, Inc. Pd-i antagonists and methods for treating infectious disease
SG11201707182WA (en) 2015-03-05 2017-10-30 Hutchinson Fred Cancer Res Immunomodulatory fusion proteins and uses thereof
EP3770168A1 (en) * 2015-05-18 2021-01-27 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
PT3310805T (pt) * 2015-06-19 2021-05-19 Kobold Sebastian Proteínas de fusão pd-1-cd28 e a sua utilização em medicina
TWI833684B (zh) 2015-06-25 2024-03-01 美商生物細胞基因治療有限公司 嵌合抗原受體(car)、組合物及其使用方法
CN106929523A (zh) * 2015-12-29 2017-07-07 中国人民解放军第二军医大学 酵母表达重组hCD80-GPI融合蛋白的制备及其在抗肿瘤中的应用
US20180186855A1 (en) * 2016-03-23 2018-07-05 Alector Llc Chimeric receptors and methods of use thereof
US11365237B2 (en) 2016-03-23 2022-06-21 Helmholtz Zentrum Muenchen—Deutsches Forschungszentrum Fuer Gesundheit Und Umwelt (Gmbh) Fusion proteins of PD-1 and 4-1BB
EP3231813A1 (en) * 2016-03-29 2017-10-18 F. Hoffmann-La Roche AG Trimeric costimulatory tnf family ligand-containing antigen binding molecules
KR102614675B1 (ko) 2016-04-15 2023-12-19 메모리얼 슬로안 케터링 캔서 센터 유전자이식 t 세포 및 키메라 항원 수용체 t 세포 조성물 및 관련 방법
AU2017248830B2 (en) * 2016-04-15 2023-03-09 Alpine Immune Sciences, Inc. CD80 variant immunomodulatory proteins and uses thereof
SG11201808457PA (en) * 2016-04-15 2018-10-30 Alpine Immune Sciences Inc Icos ligand variant immunomodulatory proteins and uses thereof
JP7467117B2 (ja) * 2016-10-07 2024-04-15 ノバルティス アーゲー 癌の治療のためのキメラ抗原受容体
US11725210B2 (en) 2017-03-17 2023-08-15 Fred Hutchinson Cancer Center Immunomodulatory fusion proteins and uses thereof
CN108866003A (zh) * 2017-05-16 2018-11-23 科济生物医药(上海)有限公司 基因工程化的细胞及应用
CN118853581A (zh) * 2017-06-21 2024-10-29 美商生物细胞基因治疗有限公司 嵌合抗原受体(CARs)、组合物及其使用方法
WO2019084234A1 (en) * 2017-10-26 2019-05-02 St. Jude Childen's Research Hospital, Inc. METHODS AND COMPOSITIONS FOR TREATING CD33 + CANCERS AND IMPROVING IN VIVO PERSISTENCE OF CHIMERIC ANTIGEN RECEPTOR T CELLS
IL326873A (en) * 2017-12-29 2026-04-01 Memorial Sloan Kettering Cancer Center Enhanced chimeric antigen receptors and uses thereof

Similar Documents

Publication Publication Date Title
US20230071733A1 (en) Immunoconjugates
CA2791383C (en) Compositions and methods for targeted immunomodulatory antibodies and fusion proteins
RU2761377C2 (ru) Иммуноконъюгаты антитела к pd-1 с мутантом il-2 или с il-15
JP2020525536A5 (cg-RX-API-DMAC7.html)
JP2017537925A5 (cg-RX-API-DMAC7.html)
JP2025517479A (ja) Bcma-cd19を標的とする二重特異性キメラ抗原受容体およびその用途
AU2021383237A1 (en) Nkg2a-targeting antibody and use thereof
JP2024525492A5 (cg-RX-API-DMAC7.html)
JP7812549B2 (ja) 人工免疫監視キメラ抗原受容体(ai-car)及びそれを発現する細胞
AU2024244733B2 (en) Bispecific chimeric antigen receptors targeting cd20 and bcma
JP2022513372A5 (cg-RX-API-DMAC7.html)
JP2024514974A5 (cg-RX-API-DMAC7.html)
WO2020087116A1 (en) Bispecific polypeptides for engagement of car expressing immune cells with antigen presenting cells and uses thereof
JP2026513997A (ja) Bcma及びcd19を標的とする二重特異性キメラ抗原受容体
JP2022548112A5 (cg-RX-API-DMAC7.html)
CN120476143A (zh) 包含与il18组合的新型cd19结合剂的car-t构建体及其使用方法
CN115873802A (zh) 嵌合抗原受体免疫细胞及其制法和应用
RU2022103913A (ru) Слитый полипептид для иммунотерапии
KR20190028343A (ko) 뉴로필린 1 (Neuropilin 1, NRP1)에 특이적으로 결합하는 펩타이드를 포함하는 조절 T 세포의 활성을 억제하기 위한 조성물
EP4566619A1 (en) Targeting modules against cd19 and cd20 for use in a method for stimulating a reversed chimeric antigen receptor-mediated immune response in a mammal
HK40125822A (en) Targeting modules against cd19 and cd20 for use in a method for stimulating a reversed chimeric antigen receptor-mediated immune response in a mammal
AU2023289687A1 (en) Targeting modules against cd123 for use in a method for stimulating a chimeric antigen receptor-mediated immune response in a mammal
WO2025081163A1 (en) Compositions for the treatment of cancer